Harbour BioMed Subsidiary Nona Biosciences Enters into Exclusive Global Licensing Agreement with Pfizer for MSLN-Targeting ADC HBM9033

　　Harbour BioMed-B(02142) rose 8.28% at midday, trading at HKD 1.70, with a turnover of HKD 8.241 million.

Harbour BioMed Subsidiary Nona Biosciences Announces Exclusive Licensing Agreement with Pfizer for Global Clinical Development and Commercialization of MSLN-Targeted Antibody-Drug Conjugate (ADC) HBM9033. Nona Biosciences will receive $53 million in upfront and near-term payments, up to $1.05 billion in milestone payments, and is also eligible to receive tiered royalties on net sales.

Editor: Lu Yujun